NEW YORK – Bio-Techne said on Thursday that its Lunaphore subsidiary has partnered with Discovery Life Sciences to add its Comet spatial biology platform to Discovery's suite of specialty laboratory services.
Discovery's Lunaphore Comet Hyperplex Immunofluorescence Services are intended to facilitate the development of next-generation assays for clinical trials and "provide multidimensional spatial biology insights to advance biomarker discovery, patient stratification, and translational medicine," Bio-Techne said in a statement.
"By integrating COMET with Discovery's molecular pathology expertise, this partnership is poised to drive biomedical research breakthroughs," Discovery CEO Greg Herrema said. "This new service combined with our rigorous regulatory compliance processes will provide pharmaceutical companies with the ability to develop Clinical Laboratory Improvement Amendment (CLIA)-compliant hyperplex tests."
Comet is a fully automated, high-throughput, hyperplex platform that allows for the simultaneous analysis of RNA and protein data within the spatial context of tissues to improve understanding of cellular dynamics and disease processes.
Discovery provides biospecimen products to pharmaceutical, biotechnology, and diagnostic companies and offers specialty laboratory services, such as genomics, proteomics, and molecular pathology, to support prospective and retrospective clinical trials.